ACS omega · 2026
Label-Free Nanostructured Biosensing Platform Based on Depolarized Dynamic Light Scattering for Rapid and Portable Detection of Immunoglobulins in Complex Biological Samples.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Junqueira Caroline Magalh̃aes, Goņcalves Kennedy Batista, Macedo Ĺıvia de Brito, Mendez Patrick Gonçalves, Costa Nick Rocha, Apolińario Iara Borges, Jorge Enzo Morrison Figueiredo Costa, Goņcalves Amanda Bonoto, Lage Anna Carolina Pinheiro, Santos Daniel de Assis, da Fonseca Fĺavio Guimar̃aes, Barcelos Rosimeire Coura, Junior Ary Corr̂ea, Ladeira Luiz Orlando, de Mesquita Oscar Nassif, Gomes Ĺıvia Siman
Аннотация
The dynamic behavior of nanoparticles in solution provides valuable insights for biomolecular detection. When nanoparticles exhibit optical anisotropy, their Brownian rotational diffusion can be monitored through depolarized dynamic light scattering (DDLS). For anisotropic particles such as gold nanorods (GNRs), the rotational diffusion coefficient scales inversely with the cube of their hydrodynamic radius, making DDLS highly sensitive to nanoscale binding events. Here, we report a label-free nanostructured biosensing platform based on DDLS that enables rapid, sensitive, and portable detection of immunoglobulins in complex samples. The system integrates bioconjugated GNRs with a custom-built, miniaturized DDLS device to achieve real-time, in loco measurements within approximately ≈10 s, without extensive sample preprocessing. As a proof-of-concept, GNRs functionalized with SARS-CoV-2 nucleocapsid proteins were used to detect specific immunoglobulins in clinical samples. The nanobiosensor exhibited high analytical sensitivity, with a detection limit of 0.16 ng/mL, as determined using spiked samples containing commercial monoclonal anti-N antibodies, highlighting its potential for rapid point-of-care immunoassays in complex biological environments.